GW Pharma Looks Forward To EU Epidyolex Launch

 
• By Maureen Kenny

Anticipating pan-EU approval of Epidyolex within the next six months, GW Pharmaceuticals is gearing up to launch what would be the first plant-derived cannabinoid medicine to be approved under the EU centralized procedure.

Illustration of an European Union long shadow flag with a dart board - Vector
GW has specific EU markets in its sights • Source: Shutterstock

More from Business

More from Scrip